Back to Results
First PageMeta Content
Protease inhibitors / Health / HIV/AIDS / Virology / Hepatitis / Peginterferon alfa-2a / MiR-122 / Hepatitis C virus / Telaprevir / Biology / Medicine / Antivirals


17 AprilAnalyst Stuart RobertsAssociate Analyst Tanushree Jain
Add to Reading List

Document Date: 2014-02-16 20:47:19

Open Document

File Size: 1,02 MB

Share Result on Facebook

City

Bristol / Princeton / Basel / Sydney / South San Francisco / Watertown / South Plainfield / Hørsholm / San Jose / Foster City / San Diego / /

Company

Biotron / Chiron / LG Life Sciences / Metabasis Therapeutics / It 45 46 / Genelabs / Idenix / Okairos AG / Flamel Technologies / Immune Deficiency Syndrome / Bristol-Myers Squibb / Merck & Co. / Zymogenetics / Pfizer / Enanta Pharmaceuticals / Inhibitex / BMS for US / Anadys Pharmaceuticals / Novartis Venture Funds / Biota / Southern Cross Equities / J&J / Roche / Achillion / Santaris Pharma / MERCK / Pharmasset / Intermune / Ligand Pharmaceuticals / HCV / HIV Expected Return Capital / Bell Potter Securities / Schering Plough Human Genome Sciences / GSK / Versant Ventures / Gilead Sciences / SCHERING-PLOUGH / Vertex / /

Country

Brazil / United Kingdom / China / Denmark / Italy / Mexico / Malaysia / Spain / South Africa / France / Japan / Korea / Romania / Saudi Arabia / Poland / Belgium / Turkey / United States / Greece / /

Currency

USD / cent / AUD / /

Event

FDA Phase / Funding / Product Issues / M&A / Reorganization / /

Facility

Biotron’s library / Biotron’s pipeline / University of Alberta / /

IndustryTerm

liver disease accounting / HCV treatment / partial underwriter / treatment of Hepatitis C / platform technology / HIV therapy / immune systems / well-funded healthcare systems / technology development process / healthcare systems / /

MarketIndex

S&P 300 / /

MedicalCondition

HIV / microbial infections / dengue viruses / strong commercial interest Chronic Hepatitis C / chronic HCV / dengue virus / infection / chronic infection / Previously Hepatitis C / Hepatitis C / infections / influenza / disease / SARS / influenza infections / liver cancer / both infections / cirrhosis / Hepatitis / liver disease / viral infections / opportunistic infection / AIDS / dengue / muscular dystrophy / Non-B Hepatitis / Acquired Immune Deficiency Syndrome / influenza virus / cystic fibrosis / HIV infection / Opportunistic Infections / prophylactic Hepatitis C / inflammation / Chronic Hepatitis C / /

Organization

University of Alberta / Boehringer Ingelheim Venture Fund / World Health Organisation / FDA / European Union / UNAIDS / /

Person

Michelle Miller / Ann Intern Med / Michael Houghton / Stuart Roberts / Michael Hoy / Ann Intern / Denis Wade / /

Position

CEO / good representative / Pharmaceutical Executive / good CEO / partial underwriter / Major / Analyst / Fairfax executive / executive / /

Product

Novartis 45 552 / Copegus / ribavirin / Pegasys / Rebetol / Gilead 5 110 5 / 2a / peginterferon / Roche 0 168 4 / Roche 60 530 / polyethylene glycol / Pegintron / Biotron BIT225 / BIT225 / Dec-07 / Sydney-based drug / HCV / 3Q2012 / Sep-06 / 2Q2012 / observers / PSI-7977 / Mar-06 / HIV/HCV / Feb-10 / Risk Speculative An HCV compound / HCV vaccine / /

ProvinceOrState

Alberta / New Jersey / HCV / Georgia / /

Technology

Virion platform technology / drug delivery / drug discovery / genotype / alpha / antibodies / platform technology / Medusa technology / rational drug design / drug development / /

URL

www.okairos.com / www.flamel.com / www.pegintron.com / www.enzon.com / www.pegasys.com / www.tacerebio.com / www.biota.com.au / www.gilead.com / www.ptcbio.com / www.santaris.com / www.regulusrx.com / www.enanta.com / www.retroconference.org / www.aliosbiopharma.com / /

SocialTag